Trial · NCT03011372
Results by group17
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 17 of 17
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Who Achieved Complete Response (CR) as Determined by Investigator Assessment According to the Response Criteria for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement | Pemigatinib 13.5 mg | 68.9 | 95% Confidence Interval 53.35 to 81.83 | percentage of participants | |
| Percentage of Participants Who Achieved CR as Determined by Central Review Committee (CRC) Assessment | Pemigatinib 13.5 mg | 68.9 | 95% Confidence Interval 53.35 to 81.83 | percentage of participants | |
Percentage of Participants Who Achieved a Best Overall Response of Complete Response (CR) or Partial Response (PR) as Determined by Investigator Assessment According to the Response Criteria for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement | Pemigatinib 13.5 mg | 77.8 | 95% Confidence Interval 62.91 to 88.80 | percentage of participants | |
| Percentage of Participants Who Achieved a Best Overall Response of CR or PR as Determined by CRC Assessment | Pemigatinib 13.5 mg | 75.6 | 95% Confidence Interval 60.46 to 87.12 | percentage of participants | |
| Percentage of Participants Who Achieved a Complete Cytogenetic Response (CCyR) as Assessed by Local Analysis and Investigator Evaluation | Pemigatinib 13.5 mg | 73.3 | 95% Confidence Interval 58.06 to 85.40 | percentage of participants | |
| Percentage of Participants Who Achieved a CCyR as Assessed by CRC Assessment | Pemigatinib 13.5 mg | 73.3 | 95% Confidence Interval 58.06 to 85.40 | percentage of participants | |
| Percentage of Participants Who Achieved a Partial Cytogenetic Response (PCyR) as Assessed by Local Analysis and Investigator Evaluation | Pemigatinib 13.5 mg | 8.9 | 95% Confidence Interval 2.48 to 21.22 | percentage of participants | |
| Percentage of Participants Who Achieved a PCyR as Assessed by CRC Assessment | Pemigatinib 13.5 mg | 15.6 | 95% Confidence Interval 6.49 to 29.46 | percentage of participants | |
| Duration of Complete Response | Pemigatinib 13.5 mg | Investigator assessment | 53.29 | 95% Confidence Interval 12.22 to NA | months |
| Duration of Complete Response | Pemigatinib 13.5 mg | CRC assessment | NA | 95% Confidence Interval 27.86 to NA | months |
| Duration of Response | Pemigatinib 13.5 mg | Investigator assessment | 53.29 | 95% Confidence Interval 15.51 to NA | months |
| Duration of Response | Pemigatinib 13.5 mg | CRC assessment | NA | 95% Confidence Interval 27.86 to NA | months |
| Progression-free Survival (PFS) | Pemigatinib 13.5 mg | Investigator assessment | 73.89 | 95% Confidence Interval 54.74 to NA | months |
| Progression-free Survival (PFS) | Pemigatinib 13.5 mg | CRC assessment | 73.89 | 95% Confidence Interval 29.17 to NA | months |
| Overall Survival | Pemigatinib 13.5 mg | NA | 95% Confidence Interval 54.74 to NA | months | |
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Pemigatinib 13.5 mg | 47 | Participants | ||
| Number of Participants With Any ≥Grade 3 TEAE | Pemigatinib 13.5 mg | 39 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03011372/results